DE602010000019D1 - Neue therapeutische Verwendungen von Inecalcitol - Google Patents

Neue therapeutische Verwendungen von Inecalcitol

Info

Publication number
DE602010000019D1
DE602010000019D1 DE602010000019T DE602010000019T DE602010000019D1 DE 602010000019 D1 DE602010000019 D1 DE 602010000019D1 DE 602010000019 T DE602010000019 T DE 602010000019T DE 602010000019 T DE602010000019 T DE 602010000019T DE 602010000019 D1 DE602010000019 D1 DE 602010000019D1
Authority
DE
Germany
Prior art keywords
inecalcitol
therapeutic uses
new therapeutic
day
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602010000019T
Other languages
German (de)
English (en)
Inventor
Remi Delansorne
Jean-Francois Dufour-Lamartinie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aton SA
Original Assignee
Hybrigenics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybrigenics SA filed Critical Hybrigenics SA
Publication of DE602010000019D1 publication Critical patent/DE602010000019D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE602010000019T 2009-05-20 2010-05-18 Neue therapeutische Verwendungen von Inecalcitol Active DE602010000019D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17990609P 2009-05-20 2009-05-20

Publications (1)

Publication Number Publication Date
DE602010000019D1 true DE602010000019D1 (de) 2011-05-26

Family

ID=42308305

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602010000019T Active DE602010000019D1 (de) 2009-05-20 2010-05-18 Neue therapeutische Verwendungen von Inecalcitol

Country Status (23)

Country Link
US (1) US8481514B2 (https=)
EP (1) EP2263677B1 (https=)
JP (2) JP2012527424A (https=)
KR (1) KR101845320B1 (https=)
CN (1) CN102448466A (https=)
AT (1) ATE505194T1 (https=)
AU (1) AU2010261967B2 (https=)
BR (1) BRPI1009056A2 (https=)
CA (1) CA2762458C (https=)
DE (1) DE602010000019D1 (https=)
DK (1) DK2263677T3 (https=)
ES (1) ES2363070T3 (https=)
HR (1) HRP20110433T1 (https=)
IL (1) IL216418A (https=)
MX (1) MX2011012330A (https=)
NZ (1) NZ596497A (https=)
PL (1) PL2263677T3 (https=)
PT (1) PT2263677E (https=)
RU (1) RU2571490C2 (https=)
SG (1) SG176581A1 (https=)
SI (1) SI2263677T1 (https=)
UA (1) UA105792C2 (https=)
WO (1) WO2010145903A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE550318T1 (de) 2010-01-26 2012-04-15 Hybrigenics Sa Neues verfahren zur isomerisierung kondensierter bicyclischer strukturen und herstellung von diese enthaltenden vitamin d analoga
US20120015913A1 (en) * 2010-07-15 2012-01-19 Delansorne Remi Formulations of 14-EPI-Analogues of Vitamin D
EP2407152A1 (en) * 2010-07-15 2012-01-18 Hybrigenics S.A. Formulations of 14-epi-analogues of vitamin D
EP2407155B1 (en) * 2010-07-15 2012-12-26 Hybrigenics S.A. Formulations of inecalcitol
EP3157533A1 (en) * 2014-06-19 2017-04-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Composition comprising a combination of dna methylation inhibitor and a vitamin d receptor agonist for the treatment of drug resistant cancer or for the prevention of tumor relapse
BR112018075206A2 (pt) 2016-06-06 2019-03-19 Celgene Corporation tratamento de malignidade hematológica com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
JP2020143008A (ja) * 2019-03-05 2020-09-10 達也 楠堂 新規褐色脂肪細胞分化誘導剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2153491C2 (ru) 1993-07-09 2000-07-27 Лаборатуар Терамекс С.А. Аналоги витамина d, соединения, способы их получения и фармацевтическая композиция
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
GB0305332D0 (en) * 2003-03-10 2003-04-09 Leuven K U Res & Dev Biological evaluation of novel vitamin D analogues
AU2005289664A1 (en) * 2004-09-24 2006-04-06 Bioxell S.P.A. 20-cycloalkyl,26,27-alkyl/haloalkyl vitamin D3 compounds and methods of use thereof

Also Published As

Publication number Publication date
US20110015276A1 (en) 2011-01-20
ES2363070T3 (es) 2011-07-19
KR20120017075A (ko) 2012-02-27
CN102448466A (zh) 2012-05-09
IL216418A0 (en) 2012-02-29
PL2263677T3 (pl) 2011-09-30
CA2762458C (en) 2018-08-28
RU2011151854A (ru) 2013-06-27
PT2263677E (pt) 2011-06-01
US8481514B2 (en) 2013-07-09
ATE505194T1 (de) 2011-04-15
IL216418A (en) 2015-09-24
DK2263677T3 (da) 2011-06-06
MX2011012330A (es) 2011-12-16
JP2016179994A (ja) 2016-10-13
NZ596497A (en) 2013-05-31
SG176581A1 (en) 2012-01-30
EP2263677A1 (en) 2010-12-22
UA105792C2 (uk) 2014-06-25
KR101845320B1 (ko) 2018-04-04
CA2762458A1 (en) 2010-12-23
RU2571490C2 (ru) 2015-12-20
SI2263677T1 (sl) 2011-07-29
AU2010261967B2 (en) 2016-03-03
WO2010145903A1 (en) 2010-12-23
EP2263677B1 (en) 2011-04-13
HRP20110433T1 (hr) 2011-07-31
AU2010261967A1 (en) 2011-12-08
BRPI1009056A2 (pt) 2020-06-02
JP2012527424A (ja) 2012-11-08

Similar Documents

Publication Publication Date Title
ATE505194T1 (de) Neue therapeutische verwendungen von inecalcitol
MX2024000208A (es) Restos de administracion terapeutica novedosos y usos de estos.
NO20071428L (no) Kombinasjon inneholdende ZD6474 og Imatinib
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
NO20060307L (no) Anvendelse av kinoazolinderivatet ZD6474 kombinert med platinaforbindelser og eventuelt ioniserende straling i behandling av sykdommer assosoiert med angiogenese og/eller okt vaskulaert permeabilitet
AR063628A1 (es) Compuestos de piridinona utiles para el tratamiento de cancer
EA201791669A2 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
CR9181A (es) Antiangiogenesis terapia de autoinmunidad de enfermedad en pacientes a quienes a fallado la terapia previa
CY1111547T1 (el) Συνδυασμος zd6474 και πεμετρεξεδης
NO20072167L (no) Kombinasjon omfattende ZD6474 og et antiandrogen
WO2005123660A3 (en) Polycationic compounds and uses thereof
WO2012142615A3 (en) Auranofin and auranofin analogs useful to treat proliferative disease and disorders
CY1111482T1 (el) Συνδυασμος azd2171 και πεμετρεξεδης
UY29161A1 (es) Nuevos heterociclos
JP2012527424A5 (https=)
NO20076657L (no) Kombinasjonsterapi av cancer med AZD2171 og gemcitabin
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
ATE447973T1 (de) Kombinationstherapie mit azd-2171
NO20064753L (no) Kombinasjonsterapi
MXPA05013975A (es) Tratamiento de enfermedades asociadas con amiloide y epileptogenesis.
BRPI0509881A (pt) combinação terapêutica para tratamento da doença de alzheimer
WO2006055381A3 (en) Prodrugs of (2r)-2-propyloctanoic acid for treatment of stroke
WO2004103291A3 (en) Extended release compositions of proton pump inhibitor